A new blood test sharpens the diagnosis of Alzheimer’s disease
A study has validated clinical cut-off points for a new blood test that measures phosphorylated tau 217 (p-tau217), a key biomarker for Alzheimer’s disease. Using two commercial assays, researchers established thresholds that achieved high diagnostic accuracy (over 94%) when compared to traditional methods like cerebrospinal fluid analysis and amyloid PET scans. The test, which is now available in a certified clinical laboratory, was found to be stable across different handling conditions, paving the way for its use in routine memory clinics and a forthcoming randomised trial to assess its impact on clinical decision-making.
Why it might matter to you:
As a neuroscientist focused on chronic pain and neurobiology, you understand the critical importance of reliable biomarkers for understanding and intervening in neurological disorders. The validation of a practical, blood-based test for Alzheimer’s represents a significant methodological advance in clinical neurology. This shift towards accessible, objective diagnostics could influence how you conceptualise and pursue biomarker discovery in your own research on pain mechanisms and treatment responses.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
